IART Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
418.8M
+6.8%
391.9M
-9.9%
434.9M
+8.2%
402.1M
-3.3%
415.6M
Cost of Revenue
199.0M
+13.8%
174.9M
-18.3%
214.1M
+9.7%
195.1M
-5.4%
206.3M
Gross Profit
219.7M
+1.3%
217.0M
-1.8%
220.9M
+6.7%
207.0M
-1.1%
209.3M
Operating Expenses
200.5M
-2.5%
205.5M
+3.9%
197.8M
+1.3%
195.2M
-73.0%
722.0M
R&D
24.3M
+3.2%
23.5M
-5.2%
24.8M
+10.4%
22.5M
-16.8%
27.0M
SG&A
172.4M
-3.3%
178.2M
+5.3%
169.3M
+0.1%
169.0M
-6.0%
179.9M
Operating Income
19.3M
+68.1%
11.5M
-50.2%
23.0M
+95.9%
11.8M
+102.3%
-512674000
EBITDA
57.4M
+15.1%
49.9M
-18.8%
61.5M
+22.2%
50.3M
+38.2%
36.4M
Net Income
4.5M
+197.1%
-4617000
-171.0%
-1704000
+68.5%
-5404000
+98.9%
-484073000
EPS (Basic)
$0.06
+200.0%
$-0.06
-200.0%
$-0.02
+71.4%
$-0.07
+98.9%
$-6.31
EPS (Diluted)
$0.06
+200.0%
$-0.06
-200.0%
$-0.02
+71.4%
$-0.07
+98.9%
$-6.31
Shares (Diluted)
78.2M
+1.6%
77.0M
+0.2%
76.8M
+0.0%
76.8M
+0.1%
76.7M
Integra LifeSciences (IART) โ€” Financials